Evgen Pharma PLC Hardman Res.: Funded to the end of Phase II trials
11 Dicembre 2017 - 8:15AM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
11 December 2017
Hardman Research: Funded to the end of Phase II trials
Increased funding to the end of Phase II trials: Evgen is a
virtual pharmaceutical company focused on the development of a
synthetic version of a natural product, sulforaphane, which is
known to modulate key signalling pathways involved in cellular
protection and inflammation. Evgen's proprietary technology,
Sulforadex, creates new and stable variants of sulforaphane,
enabling it to be used as a therapeutic for the first time. SFX-01
is progressing in Phase II clinical trials for both subarachnoid
haemorrhage and ER+ breast cancer, with readouts expected in or
around the end of 2018. EVG has strengthened its balance sheet with
a Placing to raise new funds of GBP2.3m gross.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/evgen-pharma-documents/11.12.17-funded-to-the-end-of-phase-ii-trials.pdf
To contact us: Analysts:
Hardman & Co Dr Martin Hall mh@hardmanandco.com
35 New Broad Street Dr Dorothea Hill dmh@hardmanandco.com
London Dr Gregoire Pave gp@hardmanabdco.com
EC2M 1NH Telephone: +44 20 7194 7622
Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABIBDDXDGBGRI
(END) Dow Jones Newswires
December 11, 2017 02:15 ET (07:15 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024